Exavir Therapeutics develops prodrug nanomedicine technology that extends the half-life of small molecule drugs by over 100 times, enabling ultra-long-acting injectable therapies for chronic viral infections and CNS disorders. Their initial focus is on creating integrase inhibitors for HIV treatment and prevention, addressing the low adherence rates associated with daily oral therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients with chronic viral infections and CNS disorders struggle with adherence to daily oral medication regimens, leading to suboptimal treatment outcomes. Current therapies often require frequent dosing, which can be inconvenient and contribute to inconsistent drug levels in the body. This is particularly problematic for diseases like HIV, where consistent medication adherence is crucial for preventing viral resistance and disease progression.
Solution
Exavir Therapeutics is developing ultra-long-acting injectable therapies using a prodrug nanomedicine technology that extends the half-life of small molecule drugs by over 100 times. This technology enables less frequent dosing, potentially improving patient adherence and maintaining consistent drug levels. Their initial focus is on HIV treatment and prevention, specifically developing integrase inhibitors that can be administered as infrequent injections, offering a more convenient and effective alternative to daily oral medications. The extended release formulation aims to provide sustained therapeutic drug concentrations, reducing the risk of viral rebound and improving overall treatment efficacy.
Target Audience
The primary target audience includes individuals with chronic viral infections such as HIV, patients with CNS disorders requiring long-term medication, and healthcare providers seeking to improve patient adherence and treatment outcomes.
Features
- Prodrug nano-formulation technology that prolongs the apparent half-life of small molecule drugs by >100X.
- Ultra-long-acting injectable formulations for extended release and less frequent dosing intervals.
- Focus on integrase inhibitors for HIV treatment and prevention.
- Potential application to other chronic viral infections and CNS disorders, including opioid use disorder and schizophrenia.
- Novel composition of matter enabling optimal drug properties.